LATAM MedTech Insights

In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt.This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore...

This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard.We explore why existing FDA or CE Mark documentation is no...

This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico.We dive...

Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared...

This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology.But this speed comes with a hidden cost. The new framework also introduces some of the strictest...

This week, we dive into a critical regulatory update from Brazil. ANVISA has just rolled out a new resolution that reshapes the essential safety and performance requirements for medical devices, placing a heavy new emphasis on lifecycle risk management and international harmonization. This change impacts everything from technical file preparation to post-market surveillance.We explore the...

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just launched a new, expedited approval pathway for AI-powered medical software, potentially slashing market entry timelines. This episode breaks down the immense opportunity this presents for MedTech innovators looking to enter Latin America's largest market.But there's a critical catch. This accelerated access comes with...

This week on LATAM MedTech Insights, we analyze the seismic new draft regulation from Brazil's ANVISA that is set to overhaul the rules for Software as a Medical Device (SaMD). This proposal introduces stringent new requirements for AI technologies and local data management, promising to reshape market access for all foreign MedTech companies targeting Brazil.We dive into the real-world impact by...

Brazil's regulatory agency, ANVISA, has just rolled out game-changing new rules that create a fast-track pathway for high-risk medical devices. This episode breaks down the new "reliance" mechanism that allows manufacturers to use existing international approvals for quicker market access, and what the new clinical trial law means for MedTech innovation.We explore how these changes are...

In this episode, we dissect the groundbreaking news from Brazil's health agency, ANVISA. Last week, they launched "Agiliza IA Saúde," a new fast-track approval program for AI-powered medical software. This move could unlock massive opportunities in Latin America's largest market, promising to slash registration times for innovative diagnostic technologies.While the opportunity is immense, it...